Author

L. Riva

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Gebara-Lamb· 2 shared C. W. McNamara· 2 shared K. C. Wolff· 2 shared M. G. Kirkpatrick· 2 shared A. Aziz· 1 shared A. Balmain· 1 shared A. Chatterjee· 1 shared A. Durra· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

A. Gebara-Lamb

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

High Throughput Screening with a Primary Human Mucociliary Airway Model Identifies a Small Molecule with Anti-SARS-CoV-2 Activity

C. Sen, T. M. Rickabaugh, A. V. Jeyachandran, C. Yuen, M. Ghannam, A. Durra, A. Aziz, K. Castillo, G. Garcia, A. Purkayastha, B. Han, F. W. Boulton, E. Chekler, R. Garces, K. C. Wolff, , B. Gomperts

This study uses a primary human stem cell-based airway model to screen 2100 compounds and identifies a small molecule effective against SARS-CoV-2 and its Omicron variant.

bioRxiv · May 9, 2024 · PreprintCell Biology

The interplay between dormant mutated cells and tumor promotion by chronic tissue damage in determining cancer risk.

Y. R. Li, E. Kandyba, K. Halliwill, R. Delrosario, Q. Tran, N. Bayani, D. Wu, O. Mirzoeva, M. M. Reeves, M. Islam, L. Riva, E. N. Bergstrom, K. Achanta, J. Digiovanni, L. Alexandrov, A. Balmain

This study analyzes mouse skin tumors to determine how environmental factors like TPA, obesity, and wounding affect mutational burden and cancer risk, finding that tumor promoters, not mutation number, limit tumor growth.

bioRxiv · Jan 24, 2024 · PreprintCancer Biology

Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Covalent Warhead

N. G. R. D. Elshan, K. C. Wolff, L. Riva, A. K. Woods, G. Grabovyi, K. Wilson, A. Rahimi, J. Pedroarena, S. Ghorai, A. K. Gupta, A. Nazarian, F. Weiss, Y. Liu, W. Mazumdar, L. Song, , A. K. Chatterjee

This paper introduces CMX990, a potent SARS-CoV-2 3CL protease inhibitor with improved potency and clearance compared to nirmatrelvir, advancing to Phase 1 clinical trials.

bioRxiv · Oct 24, 2023Microbiology

A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals

L. Riva, S. Yuan, X. Yin, L. Martin-Sancho, N. Matsunaga, S. Burgstaller, L. Pache, P. De Jesus, M. V. Hull, M. Chang, J. F. W. Chan, J. Cao, V. Kwok-Man Poon, K. Herbert, T.-T. Nguyen, , S. Chanda

This study identifies 30 known drugs that inhibit SARS-CoV-2 replication, with six showing effective concentrations likely to be therapeutic in patients.

bioRxiv · Apr 16, 2020 · PreprintMicrobiology